Lopinavir/Ritonavir
- Generic Name
- Lopinavir/Ritonavir
A Prospective/Retrospective,Randomized Controlled Clinical Study of Antiviral Therapy in the 2019-nCoV Pneumonia
- Conditions
- 2019-nCoV
- Interventions
- First Posted Date
- 2020-02-05
- Last Posted Date
- 2020-03-17
- Lead Sponsor
- Tongji Hospital
- Target Recruit Count
- 400
- Registration Number
- NCT04255017
- Locations
- 🇨🇳
Department and Institute of Infectious Disease, Wuhan, Hubei, China
Antiretroviral Regime for Viral Eradication in Newborns
- Conditions
- HIV/AIDS and Infections
- Interventions
- First Posted Date
- 2016-03-18
- Last Posted Date
- 2022-09-28
- Lead Sponsor
- National Center for Women and Children's Health, China CDC
- Target Recruit Count
- 600
- Registration Number
- NCT02712801
- Locations
- 🇨🇳
Maternal and Child Health Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi, China
🇨🇳Maternal and Child Health Hospital of Guangdong Province, Guangzhou, Guangdong, China
🇨🇳Maternal and Child Health Hospital of Xinjiang Uygur Autonomous Region, Urumqi, Xinjiang, China
The Effectiveness of Dual Therapy (Lopinavir/Ritonavir + LamivudinE) in Treatment-Experienced HIV Infected Patients in the Russian Federation
- First Posted Date
- 2015-10-20
- Last Posted Date
- 2019-06-06
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 216
- Registration Number
- NCT02581202
Study Assessing the Effects of Darunavir/Ritonavir or Lopinavir/Ritonavir on the Pharmacokinetics of Daclatasvir in Healthy Participants
- Conditions
- Hepatitis C
- Interventions
- First Posted Date
- 2014-06-09
- Last Posted Date
- 2015-11-30
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 49
- Registration Number
- NCT02159352
- Locations
- 🇺🇸
Healthcare Discoveries, Llc D/B/A Icon Development Solutions, San Antonio, Texas, United States
Antiretroviral Regimens Containing Raltegravir for Prophylaxis of Mother-to-child-transmission of HIV Infection
- First Posted Date
- 2013-05-16
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- Fundação Bahiana de Infectologia
- Target Recruit Count
- 33
- Registration Number
- NCT01854762
- Locations
- 🇧🇷
Fundação Bahiana de Infectologia/SEI, Salvador, Bahia, Brazil
Drug-drug Interaction Study Between Lopinavir/Ritonavir and Isavuconazole
- Conditions
- Healthy VolunteersPharmacokinetics of IsavuconazolePharmacokinetics of Lopinavir/Ritonavir
- Interventions
- First Posted Date
- 2012-08-08
- Last Posted Date
- 2015-02-23
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 68
- Registration Number
- NCT01660477
- Locations
- 🇺🇸
Parexel International, Glendale, California, United States
Optimal Dosing of 1st Line Antituberculosis and Antiretroviral Drugs in Children (a Pharmacokinetic Study)
- Conditions
- TuberculosisHIV
- Interventions
- First Posted Date
- 2012-07-11
- Last Posted Date
- 2017-10-27
- Lead Sponsor
- University of Cape Town
- Target Recruit Count
- 200
- Registration Number
- NCT01637558
- Locations
- 🇿🇦
Desmond Tutu Centre, Cape Town, Western Cape, South Africa
🇿🇦KIDCRU, Tygerberg Hospital, Department of Paediatrics and Child Health, Stellenbosch University, South Africa., Cape Town, Western Cape, South Africa
🇲🇼Queen Elizabeth Central Hospital, Blantyre, Malawi
Comparing PI-Based to a nNRTI-based ART for Clearance of Plasmodium Falciparum Parasitemia in HIV-Infected
- Conditions
- HIV-1 InfectionPf Subclinical Parasitemia
- Interventions
- Drug: Trimethoprim/sulfamethoxazole
- First Posted Date
- 2012-07-03
- Last Posted Date
- 2019-08-06
- Lead Sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
- Target Recruit Count
- 52
- Registration Number
- NCT01632891
- Locations
- 🇰🇪
AMPATH at Moi Univ. Teaching Hosp. Eldoret CRS (12601), Eldoret, Kenya
🇰🇪Walter Reed Project - Kenya Med. Research Institute Kericho CRS (12501), Kericho, Kenya
🇲🇼College of Med. JHU CRS (30301), Blantyre, Malawi
Study of Options for Second-Line Effective Combination Therapy (SELECT)
- Conditions
- HIV-1 Infection
- Interventions
- Drug: Abacavir/lamivudine/zidovudineDrug: Abacavir/lamivudine
- First Posted Date
- 2011-05-12
- Last Posted Date
- 2021-08-05
- Lead Sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
- Target Recruit Count
- 515
- Registration Number
- NCT01352715
- Locations
- 🇧🇷
Instituto de Pesquisa Clinica Evandro Chagas (12101), Rio de Janeiro, Brazil
🇲🇼University of North Carolina Lilongwe CRS (12001), Lilongwe, Malawi
🇿🇦Soweto ACTG CRS (12301), Johannesburg, South Africa
A Phase II/III Trial of Lopinavir/Ritonavir Dosed According to the WHO Pediatric Weight Band Dosing Guidelines
- First Posted Date
- 2010-07-29
- Last Posted Date
- 2021-11-05
- Target Recruit Count
- 97
- Registration Number
- NCT01172535
- Locations
- 🇺🇸
University of California, UC San Diego CRS, La Jolla, California, United States
🇺🇸Boston Medical Center Ped. HIV Program NICHD CRS, Boston, Massachusetts, United States
🇧🇷Hosp. Santa Casa Porto Alegre Brazil NICHD CRS, Porto Alegre, Rio Grande Do Sul, Brazil
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.